Clinical Trial Detail

NCT ID NCT01506973
Title A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

pancreatic adenocarcinoma

Therapies

Hydroxychloroquine

Gemcitabine

Age Groups: adult

No variant requirements are available.